267 related articles for article (PubMed ID: 25938755)
1. Clonality and Antimicrobial Susceptibility of Burkholderia cepacia complex Isolates Collected from Cystic Fibrosis Patients during 1998-2013 in Bern, Switzerland.
Lupo A; Isis E; Tinguely R; Endimiani A
New Microbiol; 2015 Apr; 38(2):281-8. PubMed ID: 25938755
[TBL] [Abstract][Full Text] [Related]
2. Combination antimicrobial susceptibility testing of Burkholderia cepacia complex: significance of species.
Abbott FK; Milne KE; Stead DA; Gould IM
Int J Antimicrob Agents; 2016 Nov; 48(5):521-527. PubMed ID: 27665523
[TBL] [Abstract][Full Text] [Related]
3.
Van Dalem A; Herpol M; Echahidi F; Peeters C; Wybo I; De Wachter E; Vandamme P; Piérard D
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914964
[TBL] [Abstract][Full Text] [Related]
4. Clonal diversity among Burkholderia cepacia complex isolates from cystic fibrosis patients in a reference unit.
Barrado L; Martinez MT; Villa J; Orellana MÁ; Viedma E; Chaves F
Enferm Infecc Microbiol Clin; 2013 Dec; 31(10):665-8. PubMed ID: 23850187
[TBL] [Abstract][Full Text] [Related]
5. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant
Zeiser ET; Becka SA; Wilson BM; Barnes MD; LiPuma JJ; Papp-Wallace KM
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848
[TBL] [Abstract][Full Text] [Related]
6. Molecular epidemiology and antibiotic susceptibility of Burkholderia cepacia-complex isolates from an Italian cystic fibrosis centre.
Golini G; Cazzola G; Fontana R
Eur J Clin Microbiol Infect Dis; 2006 Mar; 25(3):175-80. PubMed ID: 16501927
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Burkholderia cepacia complex species in cystic fibrosis patients in Argentina during the period 2011-2015.
Cipolla L; Rocca F; Martinez C; Aguerre L; Barrios R; Prieto M
Enferm Infecc Microbiol Clin (Engl Ed); 2018; 36(7):431-434. PubMed ID: 29055510
[TBL] [Abstract][Full Text] [Related]
8. Burkholderia cepacia complex infection in an Adult Cystic Fibrosis unit in Madrid.
Correa-Ruiz A; Girón R; Buendía B; Medina-Pascual MJ; Valenzuela C; López-Brea M; Sáez-Nieto JA
Enferm Infecc Microbiol Clin; 2013 Dec; 31(10):649-54. PubMed ID: 23528342
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
Zhou J; Chen Y; Tabibi S; Alba L; Garber E; Saiman L
Antimicrob Agents Chemother; 2007 Mar; 51(3):1085-8. PubMed ID: 17158942
[TBL] [Abstract][Full Text] [Related]
10. Hypermutation in Burkholderia cepacia complex is mediated by DNA mismatch repair inactivation and is highly prevalent in cystic fibrosis chronic respiratory infection.
Martina P; Feliziani S; Juan C; Bettiol M; Gatti B; Yantorno O; Smania AM; Oliver A; Bosch A
Int J Med Microbiol; 2014 Nov; 304(8):1182-91. PubMed ID: 25217078
[TBL] [Abstract][Full Text] [Related]
11. The first reported case of Burkholderia contaminans in patients with cystic fibrosis in Ireland: from the Sargasso Sea to Irish Children.
Power RF; Linnane B; Martin R; Power N; Harnett P; Casserly B; O'Connell NH; Dunne CP
BMC Pulm Med; 2016 Apr; 16(1):57. PubMed ID: 27103163
[TBL] [Abstract][Full Text] [Related]
12. Novel glycopolymer sensitizes Burkholderia cepacia complex isolates from cystic fibrosis patients to tobramycin and meropenem.
Narayanaswamy VP; Giatpaiboon S; Baker SM; Wiesmann WP; LiPuma JJ; Townsend SM
PLoS One; 2017; 12(6):e0179776. PubMed ID: 28662114
[TBL] [Abstract][Full Text] [Related]
13. Burkholderia cepacia complex infection in a cohort of Italian patients with cystic fibrosis.
Lambiase A; Raia V; Stefani S; Sepe A; Ferri P; Buonpensiero P; Rossano F; Del Pezzo M
J Microbiol; 2007 Jun; 45(3):275-9. PubMed ID: 17618236
[TBL] [Abstract][Full Text] [Related]
14. Two case reports of the successful eradication of new isolates of Burkholderia cepacia complex in children with cystic fibrosis.
Kitt H; Lenney W; Gilchrist FJ
BMC Pharmacol Toxicol; 2016 Mar; 17():14. PubMed ID: 27018049
[TBL] [Abstract][Full Text] [Related]
15. Identification, molecular characterisation and antimicrobial susceptibility of genomovars of the Burkholderia cepacia complex in Spain.
Medina-Pascual MJ; Valdezate S; Villalón P; Garrido N; Rubio V; Saéz-Nieto JA
Eur J Clin Microbiol Infect Dis; 2012 Dec; 31(12):3385-96. PubMed ID: 22855365
[TBL] [Abstract][Full Text] [Related]
16. [Multilocus sequence analysis, biofilm production, antibiotic susceptibility and synergy tests of Burkholderia species in patients with and without cystic fibrosis].
Akışoğlu Ö; Engin D; Sarıçam S; Müştak HK; Şener B; Hasçelik G
Mikrobiyol Bul; 2019 Jan; 53(1):22-36. PubMed ID: 30683036
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Antimicrobial Susceptibility Testing Methods for Burkholderia cenocepacia and Burkholderia multivorans Isolates from Cystic Fibrosis Patients.
Huse HK; Lee MJ; Wootton M; Sharp SE; Traczewski M; LiPuma JJ; Jorth P
J Clin Microbiol; 2021 Nov; 59(12):e0144721. PubMed ID: 34524889
[TBL] [Abstract][Full Text] [Related]
18. Activity of Tobramycin against Cystic Fibrosis Isolates of Burkholderia cepacia Complex Grown as Biofilms.
Kennedy S; Beaudoin T; Yau YC; Caraher E; Zlosnik JE; Speert DP; LiPuma JJ; Tullis E; Waters V
Antimicrob Agents Chemother; 2016 Jan; 60(1):348-55. PubMed ID: 26503664
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of
Schaumburg F; Idelevich EA; Mellmann A; Kahl BC
Microb Drug Resist; 2022 May; 28(5):545-550. PubMed ID: 35512733
[No Abstract] [Full Text] [Related]
20.
Mazer DM; Young C; Kalikin LM; Spilker T; LiPuma JJ
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
